Page 30 - Aet News Today

Walgreens has agreed to pay Humana $360 million to settle a drug pricing dispute that has spanned nearly five years. The payout is roughly half of what Walgreens was originally ordered to pay when the issue was first resolved last year.

Jill DeGraff, B.well Connected Health’s senior vice president of regulatory, believes the ONC’s new HTI-1 rule is a step in the right direction that will improve data exchange for providers, health tech vendors and patients. She applauded the rule for preserving TEFCA as a voluntary framework and for establishing FHIR-based interoperability as the industry’s de facto standard.

A recent KPMG report laid out several tailwinds and headwinds for payers in 2024. Payers' tailwinds include reduced recession worries, while their headwinds include Medicare Advantage scrutiny.

It’s high time we reframe how we think about lung cancer by ending the shame and judgment. I care less about if you quit smoking, I care more that you get screened. No one should have to die, period.

Geoff Martha sought to establish a clear line between popular understanding of AI created by apps like ChatGPT and what he believes is the significant impact that Medtronic's AI-enabled products are already having on patients and other healthcare stakeholders today.

Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the investment bank said big pharmas are looking for deals involving de-risked assets.

Medicare Advantage patients without a primary care physician are perhaps the greatest risk to health plans in 2024. Health plans must adopt best practices to reach and engage MA patients, especially those with multiple, complex conditions. Here are six best practices to consider.

The significance of credit ratings for health systems cannot be overstated. They serve as a warning sign indicating organizations need to transform. Health systems can no longer rely on top-line revenue to address their inherited problems. It is clear that a fresh approach to cost management is required to break away from past practices and chart a new course toward financial viability and sustainability.

CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follow the report of interim efficacy data showing a 75% complete response rate.

Experts have predicted that 2024 will be an eventful year for hospital M&A activity. As the industry prepares for another big year, there are a few things that health system leaders involved in these deals should keep in mind to make the process as smooth as possible, according to DexCare CEO Derek Streat.